Updated Story The Biden administration has decided to change long-standing policy and let high drug prices be a reason to step in and seize patents under rarely used march-in-rights, following years of pressure from drug-price control advocates to do so. But drug-pricing advocates said they plan to closely scrutinize the administration’s new march-in framework, unveiled Thursday morning (Dec. 7) for public comment, saying the details will determine whether the policy shift is ultimately useful in fighting monopoly...